Amlodipine vs Nifedipine in Chronic Hypertension
Amlodipine is the preferred choice over extended-release nifedipine for chronic hypertension due to superior once-daily dosing convenience, better patient compliance, fewer vasodilatory side effects, and comparable or superior blood pressure control.
Dosing Comparison
Amlodipine
- Initial dose: 5 mg once daily 1
- Maximum dose: 10 mg once daily 1
- Dose adjustment: Wait 7-14 days between titration steps 1
- Special populations: Start at 2.5 mg once daily in elderly, fragile, or hepatically impaired patients 1
Nifedipine Extended-Release
- Typical dosing: 30-90 mg once daily 2
- Important caveat: Three 30 mg tablets produce substantially higher peak concentrations than a single 90 mg tablet and should NOT be considered interchangeable 2
- Food effect: High-fat meals increase peak concentration by 60% 2
Practical conversion: When switching from nifedipine ER to amlodipine, start with 5-10 mg once daily; approximately 60% of patients will require dose titration to achieve equivalent control 3
Efficacy
Both agents demonstrate equivalent blood pressure reduction in head-to-head trials 4. However, amlodipine achieves greater BP reduction per milligram of drug - showing 1.54 mmHg systolic and 0.57 mmHg diastolic reduction per mg, compared to nifedipine's lower potency requiring higher doses 5.
The 2024 ESC guidelines recommend dihydropyridine CCBs as first-line therapy for hypertension, without distinguishing between specific agents 6. Both drugs effectively reduce cardiovascular events when used appropriately.
Side Effect Profile
Amlodipine demonstrates a significantly superior tolerability profile:
- 27% treatment-related side effects with amlodipine vs 41% with nifedipine retard (p<0.05) 7
- Significantly fewer reports of headache and flushing with amlodipine 7
- Fewer withdrawals due to adverse events with amlodipine 4, 7
- Amlodipine's longer half-life (30-50 hours) produces more gradual vasodilation, reducing reflex tachycardia and vasodilatory symptoms 1
Common side effects for both include edema, palpitations, dizziness, and flushing, but these occur more frequently with nifedipine and at higher amlodipine doses (10 mg) 8.
Patient Compliance
Amlodipine's once-daily dosing produces markedly superior compliance compared to twice-daily nifedipine:
- All four compliance assessment methods favored amlodipine in hypertensive patients 9
- Amlodipine's 30-50 hour half-life maintains BP control even when a dose is missed, providing continuous protection during incidental non-compliance 8
- Steady-state achieved after 7-8 days of consecutive dosing 1
Renal Impairment
Both agents are safe in renal impairment, with amlodipine having a slight practical advantage:
Amlodipine
- Pharmacokinetics NOT significantly influenced by renal impairment 1
- Patients with renal failure may receive the usual initial dose without adjustment 1
- Low renal clearance (7 mL/min/mg) 8
- Does not worsen kidney function in chronic kidney disease 8
- Demonstrated renoprotective effects comparable to other antihypertensive classes 5
Nifedipine ER
- No significant alterations in pharmacokinetics reported in hemodialysis or peritoneal dialysis patients 2
- Caution advised as absorption may be modified by renal disease 2
- In renal transplant recipients, both agents showed comparable effects on graft function 10
Hepatic Impairment
Both agents require dose reduction in hepatic impairment, but amlodipine has clearer dosing guidance:
Amlodipine
- Start at 2.5 mg once daily in hepatic insufficiency 1
- Clearance decreased with 40-60% increase in AUC 1
- Specific FDA-approved dosing adjustment available
Nifedipine ER
- Longer elimination half-life and higher bioavailability in liver cirrhosis 2
- No specific dosing studied for nifedipine ER formulation in hepatic disease 2
- Caution required but less clear guidance
Drug Interactions
Both are metabolized via CYP3A4. Key differences:
Amlodipine
- 77% increase in simvastatin exposure - monitor closely 1
- 40% average increase in cyclosporine levels in renal transplant patients 1
- 2.5-4 fold increase in tacrolimus exposure in CYP3A5 expressers 1
Nifedipine
- Up to 2-fold increase in AUC with grapefruit juice - avoid grapefruit completely 2
- Similar CYP3A4 interactions expected
Special Populations
Elderly Patients
- Both require lower starting doses 1, 2
- Amlodipine: Start 2.5 mg daily 1
- Elderly patients show 36% higher peak concentrations and 70% greater average plasma concentrations with amlodipine 1
- Nifedipine elimination half-life nearly doubles in elderly (6.7h vs 3.8h) 2
Pregnancy
Neither agent is first-line for chronic hypertension in pregnancy (methyldopa, labetalol preferred).
Clinical Bottom Line
Choose amlodipine as first-line dihydropyridine CCB because:
- True once-daily dosing with forgiveness for missed doses
- 34% fewer side effects than nifedipine
- Superior patient compliance
- Clearer dosing guidance in hepatic impairment
- No food interaction concerns
- Higher potency per milligram
- Simpler titration schedule
Reserve nifedipine ER for:
- Patients who have specifically failed or are intolerant to amlodipine
- Cost considerations if generic nifedipine is substantially cheaper (though both are now generic)
The 2024 ESC guidelines support using dihydropyridine CCBs as first-line agents, preferably in combination therapy for most patients with confirmed hypertension (BP ≥140/90 mmHg) 6. When selecting between these two agents, amlodipine's practical advantages make it the superior choice for long-term chronic hypertension management.